Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vista Pharmaceuticals's Enterprise Value is ₹514.28 Mil.
Vista Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.00 Mil. Therefore, Vista Pharmaceuticals's EV-to-FCF for today is .
The historical rank and industry rank for Vista Pharmaceuticals's EV-to-FCF or its related term are showing as below:
BOM:524711'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.54 Med: 0 Max: 0
Current: -10.54
BOM:524711's EV-to-FCF is ranked worse than 100% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.24
vs BOM:524711: -10.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vista Pharmaceuticals (BOM:524711) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vista Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Vista Pharmaceuticals's share price for today is ₹6.75.
Vista Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-1.980.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vista Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vista Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vista Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vista Pharmaceuticals's EV-to-FCF falls into.
Vista Pharmaceuticals's current Enterprise Value is ₹514.28 Mil.
Vista Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Vista Pharmaceuticals (BOM:524711) Overvalued in 2026?
Based on GuruFocus' analysis, Vista Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹6.75 is trading 10.1% above its estimated GF Value™ of ₹6.13.
GuruFocus considers Vista Pharmaceuticals to be Fairly Valued.
Key valuation signals for BOM:524711:
EV-to-FCF:
GF Value™: ₹6.13 vs. price of ₹6.75 (10.1% above fair value)
No single metric tells the full story. See the BOM:524711 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vista Pharmaceuticals Ltd is an Indian company engaged in a single operating segment, which is the manufacturing of Pharmaceutical products. The company offers over-the-counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, and Indomethacin are the drugs offered by the company in a capsule dosage form. The company generates all of its operating revenue from sales within its domestic market.
47GF Score
Get the complete analysis for BOM:524711
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524711 has been successfully added to your 
